INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-148783 | Pharmaceuticals and Medical
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Influenza Virus A, H3N2 Subtype Infection Drugs Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET
7.1 GLOBAL INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA INFLUENZA VIRUS A, H3N2 SUBTYPE INFECTION DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 AbbVie Inc
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 AIMM Therapeutics BV
16.3 Aphios Corporation
16.4 Celltrion, Inc
16.5 FluGen, Inc
16.6 Glide Pharmaceutical Technologies Limited
16.7 ILiAD Biotechnologies, LLC
16.8 Inovio Pharmaceuticals, Inc
16.9 Johnson & Johnson
16.10 Medicago Inc
16.11 MedImmune, LLC
16.12 Mucosis BV
16.13 NanoViricides, Inc
16.14 OPKO Health, Inc
16.15 Sarepta Therapeutics, Inc
16.16 VBI Vaccines Inc
16.17 Visterra, Inc
16.18 Zydus Cadila Healthcare Limited
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeNEO-8877
NP-025
NSC-61610
NVINF-1
Other types
By Application
clinic
hospital
Other applications
Companies
AbbVie Inc
AIMM Therapeutics BV
Aphios Corporation
Celltrion, Inc
FluGen, Inc
Glide Pharmaceutical Technologies Limited
ILiAD Biotechnologies, LLC
Inovio Pharmaceuticals, Inc
Johnson & Johnson
Medicago Inc
MedImmune, LLC
Mucosis BV
NanoViricides, Inc
OPKO Health, Inc
Sarepta Therapeutics, Inc
VBI Vaccines Inc
Visterra, Inc
Zydus Cadila Healthcare Limited
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.